Skip to main content
Erschienen in: Lung 6/2006

01.12.2006 | LUNG CANCER

Effect of Histologic Type on Recurrence Pattern in Radiation Therapy for Medically Inoperable Patients with Stage I Non-Small-Cell Lung Cancer

verfasst von: Hitoshi Ishikawa, Yuko Nakayama, Yoshizumi Kitamoto, Tetsuo Nonaka, Hidemasa Kawamura, Katsuyuki Shirai, Hideyuki Sakurai, Kazushige Hayakawa, Hideo Niibe, Takashi Nakano

Erschienen in: Lung | Ausgabe 6/2006

Einloggen, um Zugang zu erhalten

Abstract

Japanese randomized trials showed that there was a significant impact on survival from stage I adenocarcinoma (AD) of the lung by adjuvant chemotherapy with uracil-tegaful after complete resection but there was no effect for patients with squamous cell carcinoma (SQ). The purpose of this study was to examine the correlation of tumor histology and clinical outcome of radiation therapy (RT) for stage I non-small-cell lung cancer (NSCLC) and to consider the necessity of adjuvant chemotherapy after RT for these patients. The subjects were 83 patients, 54 with SQ and 29 with AD; they had received definitive RT with the total dose ranging from 60 to 80 Gy with conventional fractionation at a daily dose of 2 Gy. The differences between SQ and AD with respect to survival and recurrence pattern were investigated. The 5-year overall survival and cause-specific survival rates were 26.5% and 49.1%, respectively. No difference in survival was observed between SQ and AD patients, and the recurrence rates were almost identical (44% for SQ and 45% for AD). However, the 5-year primary control rate of SQ was significantly poorer than that of AD (SQ: 61.5%; AD: 87.6%; p = 0.03). Conversely, the 5-year metastasis-free survival rate of SQ was significantly better than that of AD (SQ: 88.2%; AD: 53.0%; p = 0.005). The different failure pattern, according to tumor histology, indicates that taking into consideration the difference in their clinical behaviors would also be important for planning RT and surgery for early lung cancer.
Literatur
1.
Zurück zum Zitat Asamura H, Nakayama H, Kondo H, et al. (1996) Lymph node involvement, recurrence, and prognosis in resected small, peripheral, non-small-cell lung carcinomas: are these carcinomas candidates for video-assisted lobectomy? J Thorac Cardiovasc Surg 111:1125–1134PubMedCrossRef Asamura H, Nakayama H, Kondo H, et al. (1996) Lymph node involvement, recurrence, and prognosis in resected small, peripheral, non-small-cell lung carcinomas: are these carcinomas candidates for video-assisted lobectomy? J Thorac Cardiovasc Surg 111:1125–1134PubMedCrossRef
2.
Zurück zum Zitat Dillman RO, Seagren SL, Propert KJ, et al. (1990) A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 323:940–945PubMedCrossRef Dillman RO, Seagren SL, Propert KJ, et al. (1990) A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 323:940–945PubMedCrossRef
3.
Zurück zum Zitat Endo C, Sagawa M, Sakurada A, et al. (2003) Surgical treatment of stage I non-small cell lung carcinoma. Ann Thorac Cardiovasc Surg 9:283–289PubMed Endo C, Sagawa M, Sakurada A, et al. (2003) Surgical treatment of stage I non-small cell lung carcinoma. Ann Thorac Cardiovasc Surg 9:283–289PubMed
4.
Zurück zum Zitat Feld R, Rubinstein LV, Weisenberger TH (1984) Sites of recurrence in resected stage I non-small-cell lung cancer: a guide for future studies. J Clin Oncol 2:1352–1358PubMed Feld R, Rubinstein LV, Weisenberger TH (1984) Sites of recurrence in resected stage I non-small-cell lung cancer: a guide for future studies. J Clin Oncol 2:1352–1358PubMed
5.
Zurück zum Zitat Filderman AE, Shaw C, Matthay RA (1986) Lung cancer. Part I: Etiology, pathology, natural history, manifestations, and diagnostic techniques. Invest Radiol 21:80–90PubMedCrossRef Filderman AE, Shaw C, Matthay RA (1986) Lung cancer. Part I: Etiology, pathology, natural history, manifestations, and diagnostic techniques. Invest Radiol 21:80–90PubMedCrossRef
6.
Zurück zum Zitat Gauden S, Ramsay J, Tripcony L (2005) The curative treatment by radiotherapy alone of stage I non-small cell carcinoma of the lung. Chest 108:1278–1282 Gauden S, Ramsay J, Tripcony L (2005) The curative treatment by radiotherapy alone of stage I non-small cell carcinoma of the lung. Chest 108:1278–1282
7.
Zurück zum Zitat Geddes DM (1979) The natural history of lung cancer: a review based on rates of tumour growth. Br J Dis Chest 73:1–17PubMedCrossRef Geddes DM (1979) The natural history of lung cancer: a review based on rates of tumour growth. Br J Dis Chest 73:1–17PubMedCrossRef
8.
Zurück zum Zitat Gressen EL, Curran WJ (2002) Inoperable localized stage I and stage II non-small cell lung cancer. Curr Treat Options Oncol 3:75–83PubMed Gressen EL, Curran WJ (2002) Inoperable localized stage I and stage II non-small cell lung cancer. Curr Treat Options Oncol 3:75–83PubMed
9.
Zurück zum Zitat Hayakawa K, Mitsuhashi N, Nakajima N, et al. (1992) Radiation therapy for stage I–III epidermoid carcinoma of the lung. Lung Cancer 8:213–224CrossRef Hayakawa K, Mitsuhashi N, Nakajima N, et al. (1992) Radiation therapy for stage I–III epidermoid carcinoma of the lung. Lung Cancer 8:213–224CrossRef
10.
Zurück zum Zitat Hayakawa K, Mitsuhashi N, Saito Y, et al. (1999) Limited field irradiation for medically inoperable patients with peripheral stage I non-small cell lung cancer. Lung Cancer 26:137–142PubMedCrossRef Hayakawa K, Mitsuhashi N, Saito Y, et al. (1999) Limited field irradiation for medically inoperable patients with peripheral stage I non-small cell lung cancer. Lung Cancer 26:137–142PubMedCrossRef
11.
Zurück zum Zitat Izbicki JR, Passlick B, Hosch SB, et al. (1996) Mode of spread in the early phase of lymphatic metastasis in non-small-cell lung cancer: significance of nodal micrometastasis. J Thorac Cardiovasc Surg 112:623–630PubMedCrossRef Izbicki JR, Passlick B, Hosch SB, et al. (1996) Mode of spread in the early phase of lymphatic metastasis in non-small-cell lung cancer: significance of nodal micrometastasis. J Thorac Cardiovasc Surg 112:623–630PubMedCrossRef
12.
Zurück zum Zitat Kaplan E, Meier P (1958) Non-parametric estimation from incomplete observation. J Am Stat Assoc 53:457–481CrossRef Kaplan E, Meier P (1958) Non-parametric estimation from incomplete observation. J Am Stat Assoc 53:457–481CrossRef
13.
Zurück zum Zitat Kato H, Ichinose Y, Ohta M, et al. (2004) Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350:1713–1721PubMedCrossRef Kato H, Ichinose Y, Ohta M, et al. (2004) Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350:1713–1721PubMedCrossRef
14.
Zurück zum Zitat Komaki R, Scott CB, Sause WT, et al. (1997) Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588. Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group. Int J Radiat Oncol Biol Phys 39:537–544PubMedCrossRef Komaki R, Scott CB, Sause WT, et al. (1997) Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588. Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group. Int J Radiat Oncol Biol Phys 39:537–544PubMedCrossRef
15.
Zurück zum Zitat McGarry RC, Song G, des Rosiers P, Timmerman R (2002) Observation-only management of early stage, medically inoperable lung cancer: poor outcome. Chest 121:1155–1158PubMedCrossRef McGarry RC, Song G, des Rosiers P, Timmerman R (2002) Observation-only management of early stage, medically inoperable lung cancer: poor outcome. Chest 121:1155–1158PubMedCrossRef
16.
Zurück zum Zitat Miyamoto T, Yamamoto N, Nishimura H, et al. (2003) Carbon ion radiotherapy for stage I non-small cell lung cancer. Radiother Oncol 66:127–140PubMedCrossRef Miyamoto T, Yamamoto N, Nishimura H, et al. (2003) Carbon ion radiotherapy for stage I non-small cell lung cancer. Radiother Oncol 66:127–140PubMedCrossRef
17.
Zurück zum Zitat Nagata Y, Negoro Y, Aoki T, et al. (2002) Clinical outcomes of 3D conformal hypofractionated single high-dose radiotherapy for one or two lung tumors using a stereotactic body frame. Int J Radiat Oncol Biol Phys 52:1041–1046PubMedCrossRef Nagata Y, Negoro Y, Aoki T, et al. (2002) Clinical outcomes of 3D conformal hypofractionated single high-dose radiotherapy for one or two lung tumors using a stereotactic body frame. Int J Radiat Oncol Biol Phys 52:1041–1046PubMedCrossRef
18.
Zurück zum Zitat Nakagawa M, Tanaka F, Tsubota N, et al. (2005) A randomized phase III trial of adjuvant chemotherapy with UFT for completely resected pathological stage I non-small-cell lung cancer: the West Japan Study Group for Lung Cancer Surgery (WJSG)—the 4th study. Ann Oncol 16:75–80PubMedCrossRef Nakagawa M, Tanaka F, Tsubota N, et al. (2005) A randomized phase III trial of adjuvant chemotherapy with UFT for completely resected pathological stage I non-small-cell lung cancer: the West Japan Study Group for Lung Cancer Surgery (WJSG)—the 4th study. Ann Oncol 16:75–80PubMedCrossRef
19.
Zurück zum Zitat Nakayama Y, Hayakawa K, Mitsuhashi N, Saito Y, Niibe H (1997) Long-term survivors of non-small cell lung cancer after radiation therapy: the significance of histologic type. Anticancer Res 17:2769–2773PubMed Nakayama Y, Hayakawa K, Mitsuhashi N, Saito Y, Niibe H (1997) Long-term survivors of non-small cell lung cancer after radiation therapy: the significance of histologic type. Anticancer Res 17:2769–2773PubMed
20.
Zurück zum Zitat Noordijk EM, vd Poest Clement E, Hermans J, Wever AM, Leer JW (1988) Radiotherapy as an alternative to surgery in elderly patients with resectable lung cancer. Radiother Oncol 13:83–89PubMedCrossRef Noordijk EM, vd Poest Clement E, Hermans J, Wever AM, Leer JW (1988) Radiotherapy as an alternative to surgery in elderly patients with resectable lung cancer. Radiother Oncol 13:83–89PubMedCrossRef
21.
Zurück zum Zitat Onishi H, Araki T, Shirato H, et al. (2004) Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer 101:1623–1631PubMedCrossRef Onishi H, Araki T, Shirato H, et al. (2004) Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer 101:1623–1631PubMedCrossRef
22.
Zurück zum Zitat Perez CA, Pajak TF, Rubin P, et al. (1987) Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. Cancer 59:1874–1881PubMedCrossRef Perez CA, Pajak TF, Rubin P, et al. (1987) Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. Cancer 59:1874–1881PubMedCrossRef
23.
Zurück zum Zitat Petrovich Z, Stanley K, Cox JD, Paig C (1981) Radiotherapy in the management of locally advanced lung cancer of all cell types: final report of randomized trial. Cancer 48:1335–1340PubMedCrossRef Petrovich Z, Stanley K, Cox JD, Paig C (1981) Radiotherapy in the management of locally advanced lung cancer of all cell types: final report of randomized trial. Cancer 48:1335–1340PubMedCrossRef
24.
Zurück zum Zitat Pisch J, Moskovitz T, Esik O, Homel P, Keller S (2002) Concurrent paclitaxel-cisplatin and twice-a-day irradiation in stage IIIA and IIIB NSCLC shows improvement in local control and survival with acceptable hematologic toxicity. Pathol Oncol Res 8:163–169PubMedCrossRef Pisch J, Moskovitz T, Esik O, Homel P, Keller S (2002) Concurrent paclitaxel-cisplatin and twice-a-day irradiation in stage IIIA and IIIB NSCLC shows improvement in local control and survival with acceptable hematologic toxicity. Pathol Oncol Res 8:163–169PubMedCrossRef
25.
Zurück zum Zitat Rosenthal SA, Curran WJ Jr (1990) The significance of histology in non-small cell lung cancer. Cancer Treat Rev 17:409–425PubMedCrossRef Rosenthal SA, Curran WJ Jr (1990) The significance of histology in non-small cell lung cancer. Cancer Treat Rev 17:409–425PubMedCrossRef
26.
Zurück zum Zitat Sause WT, Scott C, Taylor S, et al. (1995) Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 87:198–205PubMed Sause WT, Scott C, Taylor S, et al. (1995) Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 87:198–205PubMed
27.
Zurück zum Zitat Sause W, Kolesar P, Taylor S IV, et al. (2000) Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117:358–364PubMedCrossRef Sause W, Kolesar P, Taylor S IV, et al. (2000) Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117:358–364PubMedCrossRef
28.
Zurück zum Zitat Schaake-Koning C, van den Bogaert W, Dalesio O, et al. (1992) Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326:524–530PubMedCrossRef Schaake-Koning C, van den Bogaert W, Dalesio O, et al. (1992) Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326:524–530PubMedCrossRef
29.
Zurück zum Zitat Sibley GS, Jamieson TA, Marks LB, Anscher MS, Prosnitz LR (1998) Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: the Duke experience. Int J Radiat Oncol Biol Phys 40:149–154PubMedCrossRef Sibley GS, Jamieson TA, Marks LB, Anscher MS, Prosnitz LR (1998) Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: the Duke experience. Int J Radiat Oncol Biol Phys 40:149–154PubMedCrossRef
30.
Zurück zum Zitat Slotman BJ, Antonisse IE, Njo KH (1996) Limited field irradiation in early stage (T1-2N0) non-small cell lung cancer. Radiother Oncol 41:41–44PubMed Slotman BJ, Antonisse IE, Njo KH (1996) Limited field irradiation in early stage (T1-2N0) non-small cell lung cancer. Radiother Oncol 41:41–44PubMed
31.
Zurück zum Zitat Taylor NA, Liao ZX, Cox JD, et al. (2004) Equivalent outcome of patients with clinical stage IIIA non-small-cell lung cancer treated with concurrent chemoradiation compared with induction chemotherapy followed by surgical resection. Int J Radiat Oncol Biol Phys 58:204–212PubMedCrossRef Taylor NA, Liao ZX, Cox JD, et al. (2004) Equivalent outcome of patients with clinical stage IIIA non-small-cell lung cancer treated with concurrent chemoradiation compared with induction chemotherapy followed by surgical resection. Int J Radiat Oncol Biol Phys 58:204–212PubMedCrossRef
32.
Zurück zum Zitat Thomas P, Rubinstein L (1990) Cancer recurrence after resection: T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 49:242–246 Thomas P, Rubinstein L (1990) Cancer recurrence after resection: T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 49:242–246
33.
Zurück zum Zitat Uematsu M, Shioda A, Suda A, et al. (2001) Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience. Int J Radiat Oncol Biol Phys 51:666–670PubMedCrossRef Uematsu M, Shioda A, Suda A, et al. (2001) Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience. Int J Radiat Oncol Biol Phys 51:666–670PubMedCrossRef
34.
Zurück zum Zitat Vrdoljak E, Mise K, Sapunar D, Rozga A, Marusic M (1994) Survival analysis of untreated patients with non-small-cell lung cancer. Chest 106:1797–1800PubMed Vrdoljak E, Mise K, Sapunar D, Rozga A, Marusic M (1994) Survival analysis of untreated patients with non-small-cell lung cancer. Chest 106:1797–1800PubMed
35.
Zurück zum Zitat Zimmermann FB, Bamberg M, Molls M, Jeremic B (2003) Radiation therapy alone in early stage non-small cell lung cancer. Semin Surg Oncol 21:91–97PubMedCrossRef Zimmermann FB, Bamberg M, Molls M, Jeremic B (2003) Radiation therapy alone in early stage non-small cell lung cancer. Semin Surg Oncol 21:91–97PubMedCrossRef
Metadaten
Titel
Effect of Histologic Type on Recurrence Pattern in Radiation Therapy for Medically Inoperable Patients with Stage I Non-Small-Cell Lung Cancer
verfasst von
Hitoshi Ishikawa
Yuko Nakayama
Yoshizumi Kitamoto
Tetsuo Nonaka
Hidemasa Kawamura
Katsuyuki Shirai
Hideyuki Sakurai
Kazushige Hayakawa
Hideo Niibe
Takashi Nakano
Publikationsdatum
01.12.2006
Erschienen in
Lung / Ausgabe 6/2006
Print ISSN: 0341-2040
Elektronische ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-006-0012-5

Weitere Artikel der Ausgabe 6/2006

Lung 6/2006 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.